Cambridge Enterprise

TRIMTECH Therapeutics is a biotechnology company focused on developing targeted protein degradation therapies to treat neurodegenerative diseases. Their innovative platform aims to degrade toxic protein aggregates, offering oral therapeutics with high specificity, a strong safety profile, and potential for personalized treatment approaches. This enables patients to access effective and safe treatments for neurological, inflammatory, and oncological conditions.

Illumion is a technology company specializing in energy storage solutions. It develops and manufactures a lab-based, real-time measurement device that provides detailed insights into energy storage processes at sub-micrometer scales. This device enables researchers to visualize and understand energy storage processes in real-time, optimize material usage, and identify performance limitations at the microscopic level, thereby accelerating battery development and enhancing energy storage efficiency and performance.

52 North Health is a medical technology company focused on enhancing healthcare outcomes for cancer patients. It specializes in an AI-driven, portable finger prick blood test that measures neutrophil count and C-reactive protein (CRP) levels at home. This enables early detection of neutropenic sepsis risk during chemotherapy, improving patient safety and quality of life. The device facilitates timely management of the condition, offering a reliable and cost-effective solution for both patients and healthcare providers.

AllFocal Optics revolutionizes display technology through groundbreaking nanophotonic solutions.

Upfront Diagnostics is a healthcare company focused on the development of innovative blood biomarkers aimed at enhancing medical diagnosis, particularly for stroke patients experiencing large vessel occlusions. By enabling rapid and precise identification of this stroke subtype, Upfront Diagnostics' biomarkers facilitate quicker treatment decisions by clinicians, paramedics, and nurses. This timely intervention is crucial for improving patient outcomes, as it can significantly reduce the time to treatment, thereby minimizing disabilities and fatalities associated with strokes. The company holds a portfolio of patents that safeguard its proprietary biomarkers, underscoring its commitment to advancing stroke care and improving overall healthcare efficiency.